Advisors Capital Management LLC Decreases Position in Zoetis Inc. $ZTS

Key Points

• Advisors Capital Management LLC cut its stake in Zoetis by 37.8% in Q4, selling 56,516 shares and retaining 92,969 shares worth about $11.70 million.
• Zoetis beat Q4 expectations, reporting $1.48 EPS versus $1.40 expected and $2.39B in revenue versus $2.36B, set FY2026 guidance of 7.00–7.10 EPS, and declared a $0.53 quarterly dividend (annualized $2.12, 1.8% yield).
• The stock has a consensus "Hold" rating with an average price target of $152.25, a market cap near $49.2 billion, and a one‑year trading range of $113.29–$172.23.

Advisors Capital Management LLC lessened its position in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 37.8% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 92,969 shares of the company's stock after selling 56,516 shares during the quarter. Advisors Capital Management LLC's holdings in Zoetis were worth $11,697,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in ZTS. Summit Place Financial Advisors LLC boosted its position in Zoetis by 0.4% during the third quarter. Summit Place Financial Advisors LLC now owns 19,369 shares of the company's stock worth $2,834,000 after acquiring an additional 76 shares during the last quarter. CWA Asset Management Group LLC raised its holdings in Zoetis by 1.1% in the 3rd quarter. CWA Asset Management Group LLC now owns 7,236 shares of the company's stock valued at $1,059,000 after acquiring an additional 80 shares during the last quarter. YANKCOM Partnership raised its holdings in Zoetis by 3.5% in the 4th quarter. YANKCOM Partnership now owns 2,402 shares of the company's stock valued at $302,000 after acquiring an additional 81 shares during the last quarter. Evergreen Capital Management LLC lifted its stake in shares of Zoetis by 3.3% during the 3rd quarter. Evergreen Capital Management LLC now owns 2,696 shares of the company's stock worth $394,000 after purchasing an additional 85 shares during the period. Finally, Beese Fulmer Investment Management Inc. lifted its stake in shares of Zoetis by 2.4% during the 3rd quarter. Beese Fulmer Investment Management Inc. now owns 3,672 shares of the company's stock worth $537,000 after purchasing an additional 85 shares during the period. 92.80% of the stock is currently owned by hedge funds and other institutional investors.

Zoetis Stock Up 0.0%

Shares of NYSE ZTS opened at $116.92 on Monday. The firm has a market cap of $49.18 billion, a price-to-earnings ratio of 19.42, a PEG ratio of 1.78 and a beta of 0.98. Zoetis Inc. has a 1 year low of $113.29 and a 1 year high of $172.23. The company has a debt-to-equity ratio of 2.71, a quick ratio of 1.94 and a current ratio of 3.03. The stock's 50-day simple moving average is $120.83 and its 200-day simple moving average is $125.28.

Zoetis (NYSE:ZTS - Get Free Report) last posted its quarterly earnings results on Thursday, February 12th. The company reported $1.48 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.40 by $0.08. Zoetis had a net margin of 28.24% and a return on equity of 62.02%. The firm had revenue of $2.39 billion for the quarter, compared to analysts' expectations of $2.36 billion. During the same period in the prior year, the company posted $1.40 earnings per share. The firm's quarterly revenue was up 3.0% on a year-over-year basis. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. As a group, equities analysts anticipate that Zoetis Inc. will post 7.02 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, June 2nd. Stockholders of record on Monday, April 20th will be issued a dividend of $0.53 per share. The ex-dividend date of this dividend is Monday, April 20th. This represents a $2.12 annualized dividend and a dividend yield of 1.8%. Zoetis's payout ratio is 35.22%.

Analysts Set New Price Targets

Several equities research analysts have commented on ZTS shares. BTIG Research restated a "buy" rating and set a $160.00 price target on shares of Zoetis in a research note on Thursday, February 26th. UBS Group set a $136.00 target price on Zoetis in a report on Thursday, January 29th. Bank of America increased their target price on shares of Zoetis from $135.00 to $140.00 and gave the stock a "neutral" rating in a research report on Friday, February 13th. Leerink Partners restated a "market perform" rating on shares of Zoetis in a report on Tuesday, March 10th. Finally, Weiss Ratings cut shares of Zoetis from a "hold (c-)" rating to a "sell (d+)" rating in a research report on Friday, March 27th. Seven analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Hold" and an average price target of $152.25.

Zoetis Company Profile

Zoetis Inc NYSE: ZTS is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company's offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.